One group of these novel compounds works by inhibiting Cyclin Dependent Kinases
(CDK), drug targets that control cancer cell division.
Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase
Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines" (Abstract # 971)
Over-stimulation of ErbB receptors results in the increased production of cyclin D1, a signaling molecule that activates cyclin dependent kinases
(CDKs), resulting in tumor cell proliferation.
Seliciclib, Cyclacel's orally available cyclin dependent kinase
(CDK) inhibitor, has shown encouraging anti-cancer activity in several Phase 1 and Phase 2 studies.
In April at the Annual Meeting of the American Association for Cancer Research Cyclacel reported preclinical results from a combination study of seliciclib, an orally-available cyclin dependent kinase
(CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor drugs, including erlotinib (Tarceva[R]).
Several novel agents are now in clinical trials in patients with chemoresistant breast cancer, including rucaparib, an oral small-molecule inhibitor of PARP (poly ADP-ribose polymerase), for triple-negative breast cancer; palbociclib, an oral and selective inhibitor of cyclin dependent kinases
4 and 6, in women with hormone receptor-positive / HER2-negative disease; and trastuzumab emtansine, a conjugate of trastuzum ab and the cytotoxic agent mertansine, in patients with chemoresistant HER2-positive breast cancer, Dr.
Palbociclib is an investigational oral and selective inhibitor of cyclin dependent kinases
(CDK) 4 and 6.